HARROW HEALTH, INC. (42)

Browse by Contract Category

Contracts

Second Supplemental Indenture, dated as of December 20, 2022, by and between the Company and U.S. Bank Trust Company, National Association (Filed With SEC on December 20, 2022)
Mutual Termination Agreement, dated October 7, 2022 between ImprimisRx and EyePoint Pharmaceuticals, Inc (Filed With SEC on November 14, 2022)
Description of the Companys Securities (Filed With SEC on March 10, 2022)
License Agreement, dated as of August 18, 2021, by and between the Company and Wakamoto Pharmaceutical Co., Ltd (Filed With SEC on November 9, 2021)
Consulting Agreement dated July 1, 2020 between Visionology, Inc. and Andrew R. Boll (Filed With SEC on March 8, 2021)
Notes Underwriting Agreement between the Company and B. Riley Securities, Inc., as representative of the several underwriters named therein, dated December 15, 2022 (Filed With SEC on December 16, 2022)
Common Stock Underwriting Agreement between the Company and B. Riley Securities, Inc. dated December 13, 2022 (Filed With SEC on December 16, 2022)
Asset Purchase Agreement dated December 13, 2022, between the Company and Novartis Technology, LLC and Novartis Innovative Therapies AG (Filed With SEC on December 14, 2022)
Second Amendment to Loan and Security Agreement, dated as of September 21, 2022, between the Company and Melt Pharmaceuticals, Inc (Filed With SEC on November 14, 2022)
First Amendment to Loan and Security Agreement, dated as of April 8, 2022, between the Company and Melt Pharmaceuticals, Inc (Filed With SEC on November 14, 2022)
First Amendment to Loan and Security Agreement, dated as of April 8, 2022, between the Company and Melt Pharmaceuticals, Inc (Filed With SEC on August 9, 2022)
Expansion Term Letter Agreement between Eyepoint Pharmaceuticals, Inc. and ImprimisRx, LLC dated December 6, 2021 (Filed With SEC on March 10, 2022)
Asset Purchase Agreement, dated as of December 17, 2021, by and between the Company and Novartis Technology, LLC and Novartis Ophthalmics AG (Filed With SEC on March 10, 2022)
Basic Sale and Purchase Agreement, dated as of August 18, 2021, by and between the Company and Wakamoto Pharmaceutical Co., Ltd (Filed With SEC on November 9, 2021)
Loan and Security Agreement, dated September 1, 2021, by and between the Company and Melt Pharmaceuticals, Inc (Filed With SEC on September 2, 2021)
License and Supply Agreement, dated as of July 25, 2021, by and between the Company and Sintetica, S.A (Filed With SEC on August 10, 2021)
Underwriting Agreement, dated as of June 14, 2021, by and among the Company and B. Riley Securities, Inc., as representative of the several underwriters named therein (Filed With SEC on June 17, 2021)
Securities Purchase Agreement, dated as of May 5, 2021, by and between the Company and B. Riley Securities, Inc (Filed With SEC on May 5, 2021)
Underwriting Agreement, dated as of April 15, 2021, by and between the Company and B. Riley Securities, Inc., as representative of the several underwriters named therein (Filed With SEC on April 20, 2021)
First Supplemental Indenture, dated as of April 20, 2021, by and between the Company and U.S. Bank National Association, as Trustee (Filed With SEC on April 20, 2021)
Indenture, dated as of April 20, 2021, by and between the Company and U.S. Bank National Association, as Trustee (Filed With SEC on April 20, 2021)
Underwriting Agreement, dated as of April 8, 2021, by and among Harrow Health, Inc., Eton Pharmaceuticals, Inc. and National Securities Corporation (Filed With SEC on April 8, 2021)
First Amendment to Commercial Alliance Agreement between Eyepoint Pharmaceuticals, Inc. and ImprimisRx, LLC dated November 13, 2020 (Filed With SEC on March 8, 2021)
Consulting Agreement dated July 1, 2020 between Visionology, Inc. and Mark L. Baum (Filed With SEC on March 8, 2021)
Description of the Companys Securities (Filed With SEC on March 8, 2021)
Commercial Alliance Agreement between Eyepoint Pharmaceuticals, Inc. and ImprimisRx, LLC dated August 1, 2020 (Filed With SEC on November 9, 2020)
Business Loan Agreement with Renasant Bank pursuant to the Paycheck Protection Program, dated April 27, 2020 (Filed With SEC on August 10, 2020)
Description of the Companys Securities (Filed With SEC on March 13, 2020)
Consulting Agreement dated February 13, 2020 between Stowe Pharmaceuticals, Inc. and Mark L. Baum (Filed With SEC on March 13, 2020)
Consulting Agreement dated February 13, 2020 between Stowe Pharmaceuticals, Inc. and Andrew R. Boll (Filed With SEC on March 13, 2020)
Consulting Agreement dated February 13, 2020 between Stowe Pharmaceuticals, Inc. and John P. Saharek (Filed With SEC on March 13, 2020)
License Agreement, dated July 29, 2019, among Stowe Pharmaceuticals, Inc., TGV-Health, LLC and TGV-Ophthalnix, LLC (Filed With SEC on November 13, 2019)
License Agreement, dated July 28, 2019, among Mayfield Pharmaceuticals, Inc., TGV-Health, LLC and TGV-Gyneconix, LLC (Filed With SEC on November 13, 2019)
Loan Agreement, dated July 26, 2019, by and between Park Compounding, Inc. and Noice Rx, LLC (Filed With SEC on November 13, 2019)
Asset Purchase Agreement, dated July 26, 2019, by and between Park Compounding, Inc. and Noice Rx, LLC (Filed With SEC on November 13, 2019)
Consulting Agreement dated June 3, 2019 between Mayfield Pharmaceuticals, Inc. and John P. Saharek (Filed With SEC on August 14, 2019)
Consulting Agreement dated June 3, 2019 between Mayfield Pharmaceuticals, Inc. and Mark L. Baum (Filed With SEC on August 14, 2019)
Consulting Agreement dated June 3, 2019 between Mayfield Pharmaceuticals, Inc. and Andrew R. Boll (Filed With SEC on August 14, 2019)
Joinder and Amendment to Loan and Security Agreement, dated May 24, 2019, by and between Harrow Health, Inc., each of its wholly-owned subsidiaries and SWK Funding LLC (Filed With SEC on May 29, 2019)
Asset Purchase Agreement dated February 1, 2019 between Harrow Health, Inc. and Mayfield Pharmaceuticals, Inc (Filed With SEC on May 9, 2019)
Asset Purchase Agreement dated February 1, 2019 between Harrow Health, Inc. and Elle Pharmaceuticals, Inc (Filed With SEC on May 9, 2019)
Asset Purchase Agreement dated December 11, 2018 between Imprimis Pharmaceuticals, Inc. and Melt Pharmaceuticals, Inc (Filed With SEC on February 5, 2019)